Condition: Gastric or Gastroesophageal Junction Adenocarcinoma · Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.
This is a multi-national, open-label, randomized, seamless phase II/III clinical study of UTD2 combined with fluoropyrimidine- and platinum-containing therapy to evaluate the efficacy and safety in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma untreated with systemic treatment in advanced setting.
This description comes directly from the study's public registry record.
Rongguo Qiu · 010-56315388 · Rqiu2001@yahoo.com
Always discuss trial participation with your own doctor first.
| Bioresearch Partner | Hialeah, Florida, United States | Not Yet Recruiting |
| AnYang Tumor Hospital | Anyang, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, China | Recruiting |
| Jinan Municipal Central Hospital | Jinan, China | Recruiting |
| Shandong First Medical University Affiliated Tumor Hospital | Jinan, China | Recruiting |
| Liaoning Cancer Hospital | Shenyang, China | Recruiting |
| Shanxi Cancer Hospital | Taiyuan, China | Not Yet Recruiting |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, China | Not Yet Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06841679